NEW YORK (GenomeWeb News) — DermTech International said today that it has completed California CLIA licensure of its San Diego laboratory facility.

The company also said that it has completed validation testing of its proprietary Pigmented Lesion Assay (PLA), which it plans to offer as a laboratory-developed test out of its CLIA lab.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.